Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$115.22 CAD
Change Today -2.67 / -2.26%
Volume 289.4K
VRX On Other Exchanges
New York
As of 4:00 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/15 - C$347.84
52 Week Low
11/18/15 - C$92.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

valeant pharmaceuticals inte (VRX) Details

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

16,800 Employees
Last Reported Date: 02/25/15
Founded in 1983

valeant pharmaceuticals inte (VRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.9M
President of Valeant Europe and General Manag...
Total Annual Compensation: $499.3K
Executive Vice President and Company Group Ch...
Total Annual Compensation: $5.8M
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $715.4K
Consultant and Director
Total Annual Compensation: $953.8K
Compensation as of Fiscal Year 2014.

valeant pharmaceuticals inte (VRX) Key Developments

Koskie Minsky LLP and Sutts, Strosberg LLP Announce Filing of Proposed Class Action against Valeant Pharmaceuticals and Other Defendants

Koskie Minsky LLP and Sutts, Strosberg LLP announced the filing in the Ontario Superior Court of Justice of a proposed class action against Valeant Pharmaceuticals International, Inc. and certain of the company's senior officers, including its current CEO, J. Michael Pearson. The proposed class action includes all persons who purchased or otherwise acquired Valeant's securities between January 1, 2013 and November 16, 2015. The action alleges, among other things, that Valeant did not publicly disclose its relationship with Philidor Rx Services LLC, a mail order pharmacy. When Valeant's relationship with Philidor was revealed, the price of Valeant's securities fell precipitously, causing significant damages to holders of Valeant's securities.

Valeant Pharmaceuticals International, Inc. Presents at Jefferies Autumn 2015 Global Healthcare Conference, Nov-18-2015 01:20 PM

Valeant Pharmaceuticals International, Inc. Presents at Jefferies Autumn 2015 Global Healthcare Conference, Nov-18-2015 01:20 PM. Venue: The May Fair Hotel, Stratton Street, London, United Kingdom.

Valeant Pharmaceuticals International, Inc. - Special Call

To give an overview of current plans and priorities, including the transition plan from Philidor, and an update on the company's operations


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:CN C$115.22 CAD -2.67

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,744 JPY -12.00
Eisai Co Ltd ¥8,195 JPY +1.00
Endo International PLC $62.33 USD +1.33
Mylan NV $51.74 USD -0.06
Sun Pharmaceutical Industries Ltd 739.85 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VRX Industry Range
Price/Earnings 50.7x
Price/Sales 3.1x
Price/Book 4.8x
Price/Cash Flow 11.8x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VALEANT PHARMACEUTICALS INTE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at